Alembic Pharma Q2 net surges 81% to ₹335 crore
The expansion of the collaboration with DifGen provides near-term commercial opportunities and access to U.S. manufacturing capabilities. | Photo Credit: The Hindu Alembic Pharmaceuticals shares were in the spotlight Wednesday after the generic drugmaker reported more than 81% year-on-year surge in consolidated net profit to ₹335 crore during September quarter. The profit came on a…
Read More “Alembic Pharma Q2 net surges 81% to ₹335 crore” »